Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primaquine efficacy is further complicated by both impacts of partner blood schizontocides and natural polymorphisms of cytochrome P450 2D6 impairing the necessary metabolic processing of primaquine [39–42].”
In the citing paper
“Primaquine efficacy is further complicated by both impacts of partner blood schizontocides and natural polymorphisms of cytochrome P450 2D6 impairing the necessary metabolic processing of primaquine [39–42].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Xuan, J., Chen, S., Ning, B., Tolleson, W. H., & Guo, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.009 · Cited by 103
Research works printed but not linked: 77
- Allahyari, 1984, Synthesis of certain hydroxy analogues of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes, J Med Chem, 27, 407, 10.1021/jm00369a031 · DOI
- Alvarez, 2006, Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia, AmJTrop Med Hyg, 75, 605, 10.4269/ajtmh.2006.75.605 · DOI
- Alving, 1948, Study of pentaquine and isopentaquine, therapeutic agents effective in reducing relapse rate in vivax malaria, Abstr Int Congr Trop Med Malar, 56, 58
- Alving, 1955, Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine, J Lab Clin Med, 46, 301
- Alving, 1948, Procedures used at Stateville Penitentiary for the testing of potential antimalarial agents, J Clin Invest, 27, 2, 10.1172/JCI101956 · doi:10.1172/jci101956
- Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev Pharmacol Toxicol, 39, 361, 10.1146/annurev.pharmtox.39.1.361 · DOI · Paper page
- Ashley, 2014, Primaquine: The risks and the benefits, Malar J, 13, 418, 10.1186/1475-2875-13-418 · DOI · Paper page
- Asimus, 2007, Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects, Fundam Clin Pharmacol, 21, 307, 10.1111/j.1472-8206.2007.00471.x · DOI
- Bains, 2013, African variation at cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases, Evol Med Public Health, 2013, 118, 10.1093/emph/eot010 · DOI
- Bateman, 2007, MSE with mass defect filtering for in vitro and in vivo metabolite identification, Rapid Commun Mass Spectrom, 21, 1485, 10.1002/rcm.2996 · doi:10.1002/rcm.2996
- Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, N Engl J Med, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page
- Bolchoz, 2001, Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline, J Pharmacol Exp Ther, 297, 509, 10.1016/S0022-3565(24)29564-1 · doi:10.1016/s0022-3565(24)29564-1
- Bowman, 2004, Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine, J Pharmacol Exp Ther, 309, 79, 10.1124/jpet.103.062984 · DOI
- Cappellini, 2008, Glucose-6-phosphate dehydrogenase deficiency, Lancet, 371, 64, 10.1016/S0140-6736(08)60073-2 · DOI · Paper page
- Clayman, 1952, Toxicity of primaquine in Caucasians, J Am Med Assoc, 149, 1563, 10.1001/jama.1952.72930340022010b · doi:10.1001/jama.1952.72930340022010b
- Coatney, 1953, Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency, AmJTrop Med Hyg, 2, 985, 10.4269/ajtmh.1953.2.985 · doi:10.4269/ajtmh.1953.2.985
- Crews, 2012, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype, Clin Pharmacol Ther, 91, 321, 10.1038/clpt.2011.287 · DOI · Paper page
- Crews, 2014, Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update, Clin Pharmacol Ther, 95, 376, 10.1038/clpt.2013.254 · DOI · Paper page
- Deye, 2014, Primaquine for prophylaxis of malaria: Has the CYP sailed?, J Travel Med, 21, 67, 10.1111/jtm.12080 · doi:10.1111/jtm.12080
- Di Lorenzo, 1953, Korean vivax malaria. IV. curative effect of 15milligrams of primaquine daily for 7days, AmJTrop Med Hyg, 2, 983, 10.4269/ajtmh.1953.2.983 · doi:10.4269/ajtmh.1953.2.983
- Edgcomb, 1950, Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, 9, 285
- Eichelbaum, 1987, Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22, Br J Clin Pharmacol, 23, 455, 10.1111/j.1365-2125.1987.tb03075.x · doi:10.1111/j.1365-2125.1987.tb03075.x
- Eichelbaum, 1979, Defective N-oxidation of sparteine in man: A new pharmacogenetic defect, Eur J Clin Pharmacol, 16, 183, 10.1007/BF00562059 · DOI · Paper page
- Elderfield, 1946, Alkylaminoalkyl derivatives of 8-aminoquinoline, J Am Chem Soc, 68, 1524, 10.1021/ja01212a040 · doi:10.1021/ja01212a040
- Fasinu, 2014, Enantioselective metabolism of primaquine by human CYP2D6, Malar J, 13, 507, 10.1186/1475-2875-13-507 · doi:10.1186/1475-2875-13-507
- Fletcher, 1981, Studies on the pharmacokinetics of primaquine, Bull World Health Organ, 59, 407
- Fasinu, 2016, Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes, Malar J, 10.1186/s12936-016-1270-1 · DOI
- Furuya, 2014, Reticulocytes from cryopreserved erythroblasts support Plasmodium vivax infection in vitro, Parasitol Int, 63, 278, 10.1016/j.parint.2013.11.011 · doi:10.1016/j.parint.2013.11.011
- Ganesan, 2009, Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes, Toxicol Appl Pharmacol, 241, 14, 10.1016/j.taap.2009.07.012 · DOI
- Garg, 2011, Evidence of the formation of direct covalent adducts of primaquine, 2-tert-butylprimaquine (NP-96) and monohydroxy metabolite of NP-96 with glutathione and N-acetylcysteine, J Chromatogr B Analyt Technol Biomed Life Sci, 879, 1, 10.1016/j.jchromb.2010.10.029 · doi:10.1016/j.jchromb.2010.10.029
- Garrison, 1952, Cure of Korean vivax malaria with pamaquine and primaquine, J Am Med Assoc, 149, 1562, 10.1001/jama.1952.72930340021010a · doi:10.1001/jama.1952.72930340021010a
- Gonzalez, 1988, Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22, Genomics, 2, 174, 10.1016/0888-7543(88)90100-0 · DOI
- Graves, 2015, Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission, Cochrane Database Syst Rev, 2
- Guengerich, 2007, Mechanisms of cytochrome P450 substrate oxidation: Minireview, J Biochem Mol Toxicol, 21, 163, 10.1002/jbt.20174 · DOI · Paper page
- Hanboonkunupakarn, 2014, Open-label crossover study of primaquine and dihydroartemisinin–piperaquine pharmacokinetics in healthy adult thai subjects, Antimicrob Agents Chemother, 58, 7340, 10.1128/AAC.03704-14 · DOI
- Hayeshi, 2006, The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux, Eur J Pharm Sci, 29, 70, 10.1016/j.ejps.2006.05.009 · DOI
- Hockwald, 1952, Toxicity of primaquine in Negroes, J Am Med Assoc, 149, 1568, 10.1001/jama.1952.72930340027010c · doi:10.1001/jama.1952.72930340027010c
- Hong, 1992, Activated oxygen generation by a primaquine metabolite: Inhibition by antioxidants derived from Chinese herbal remedies, Free Radic Biol Med, 12, 213, 10.1016/0891-5849(92)90029-G · doi:10.1016/0891-5849(92)90029-g
- Ingelman-Sundberg, 2005, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, 5, 6, 10.1038/sj.tpj.6500285 · DOI · Paper page
- Ingram, 2014, The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea, Malar J, 13, 488, 10.1186/1475-2875-13-488 · DOI
- Jin, 2014, Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations, J Pharmacol Toxicol Methods, 70, 188, 10.1016/j.vascn.2014.08.002 · DOI
- Jittamala, 2015, Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects, Antimicrob Agents Chemother, 59, 505, 10.1128/AAC.03829-14 · doi:10.1128/aac.03829-14
- Jones, 1953, Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30mg. daily, AmJTrop Med Hyg, 2, 977, 10.4269/ajtmh.1953.2.977 · doi:10.4269/ajtmh.1953.2.977
- Kitada, 2003, Genetic polymorphism of cytochrome P450 enzymes in Asian populations: Focus on CYP2D6, Int J Clin Pharmacol Res, 23, 31
- Krotoski, 1980, Relapses in primate malaria: discovery of two populations of exoerythrocytic stages. Preliminary note, Br Med J, 280, 153, 10.1136/bmj.280.6208.153-a · doi:10.1136/bmj.280.6208.153-a
- Kumar, 2012, Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: A medicinal chemistry perspective, Curr Med Chem, 19, 3605, 10.2174/092986712801323180 · DOI
- Lancaster, 1990, Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs, J Pharm Pharmacol, 42, 267, 10.1111/j.2042-7158.1990.tb05405.x · doi:10.1111/j.2042-7158.1990.tb05405.x
- Mahgoub, 1977, Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, 584, 10.1016/S0140-6736(77)91430-1 · DOI · Paper page
- Marcsisin, 2014, Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: Implications for the 8-aminoquinoline class of anti-malarial compounds, Malar J, 13, 2, 10.1186/1475-2875-13-2 · doi:10.1186/1475-2875-13-2
- Markus, 2015, Do hypnozoites cause relapse in malaria?, Trends Parasitol, 31, 239, 10.1016/j.pt.2015.02.003 · DOI
- McChesney, 1984, Rapid aromatic hydrogen exchange in the antimalarial primaquine, Pharm Res, 1, 184, 10.1023/A:1016356926714 · doi:10.1023/a:1016356926714
- Meyer, 1997, Molecular mechanisms of genetic polymorphisms of drug metabolism, Annu Rev Pharmacol Toxicol, 37, 269, 10.1146/annurev.pharmtox.37.1.269 · DOI · Paper page
- Mihaly, 1985, Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size, Br J Clin Pharmacol, 19, 745, 10.1111/j.1365-2125.1985.tb02709.x · DOI
- Mihaly, 1984, Pharmacokinetics of primaquine in man: Identification of the carboxylic acid derivative as a major plasma metabolite, Br J Clin Pharmacol, 17, 441, 10.1111/j.1365-2125.1984.tb02369.x · DOI · Paper page
- Morais Mda, 1993, Peroxidation of the antimalarial drug primaquine: characterization of a benzidine-like metabolite with methaemoglobin-forming activity, Xenobiotica, 23, 133, 10.3109/00498259309059369 · doi:10.3109/00498259309059369
- Morris, 2014, Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol, Antimicrob Agents Chemother, 58, 5900, 10.1128/AAC.02716-14 · doi:10.1128/aac.02716-14
- Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
- Ng, 2015, Human iPSC-derived hepatocyte-like cells support Plasmodium liver-stage infection in vitro, Stem Cell Reports, 4, 348, 10.1016/j.stemcr.2015.01.002 · DOI
- Potter, 2015, Differential CYP 2D6 metabolism alters primaquine pharmacokinetics, Antimicrob Agents Chemother, 59, 2380, 10.1128/AAC.00015-15 · doi:10.1128/aac.00015-15
- Prasad, 1985, Pharmacokinetics of primaquine in rhesus monkeys, Int J Clin Pharmacol Ther Toxicol, 23, 45
- Preissner, 2013, Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy, PLoS One, 8, 10.1371/journal.pone.0082562 · DOI · Paper page
- Pukrittayakamee, 2014, Pharmacokinetic interactions between primaquine and chloroquine, Antimicrob Agents Chemother, 58, 3354, 10.1128/AAC.02794-13 · doi:10.1128/aac.02794-13
- Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6, Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
- Pybus, 2012, CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine, Malar J, 11, 259, 10.1186/1475-2875-11-259 · DOI
- Rochford, 2013, Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity, Proc Natl Acad Sci U S A, 110, 17486, 10.1073/pnas.1310402110 · doi:10.1073/pnas.1310402110
- Scheer, 2012, Modeling human cytochrome P450 2D6 metabolism and drug–drug interaction by a novel panel of knockout and humanized mouse lines, Mol Pharmacol, 81, 63, 10.1124/mol.111.075192 · DOI
- Spaggiari, 2014, Coupling ultra-high-pressure liquid chromatography with mass spectrometry for in-vitro drug-metabolism studies, TrAC Trends Anal Chem, 63, 129, 10.1016/j.trac.2014.06.021 · DOI
- St Jean, 2016, Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial, Malar J, 15, 97, 10.1186/s12936-016-1145-5 · DOI
- Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia, Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
- Tekwani, 2015, Enantioselective pharmacokinetics of primaquine in healthy human volunteers, Drug Metab Dispos, 43, 571, 10.1124/dmd.114.061127 · doi:10.1124/dmd.114.061127
- Vale, 2009, Primaquine revisited six decades after its discovery, Eur J Med Chem, 44, 937, 10.1016/j.ejmech.2008.08.011 · DOI · Paper page
- Vasquez-Vivar, 1992, Hydroxylated metabolites of the antimalarial drug primaquine Oxidation and redox cycling, J Biol Chem, 267, 6848, 10.1016/S0021-9258(19)50504-X · DOI · Paper page
- Vasquez-Vivar, 1994, Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo, Biochem Pharmacol, 47, 309, 10.1016/0006-2952(94)90022-1 · DOI
- Vuong, 2015, Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics, Antimicrob Agents Chemother, 59, 3864, 10.1128/AAC.00343-15 · doi:10.1128/aac.00343-15
- Ward, 1985, Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects, Br J Clin Pharmacol, 19, 751, 10.1111/j.1365-2125.1985.tb02710.x · doi:10.1111/j.1365-2125.1985.tb02710.x
- Yang, 2015, Novel cytochrome P450 reaction phenotyping for low clearance compounds using hepatocyte relay method, Drug Metab Dispos
- Zanger, 2004, Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry, Naunyn Schmiedeberg's Arch Pharmacol, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
Cited by
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Metadata
- Authors
- Marcsisin, S. R., Reichard, G., & Pybus, B. S.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 161
- Pages
- 1-10
- ISSN
- 0163-7258
- Cited by
- 116
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Military Infectious Disease Research Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. https://app.cochat.ai/papers/10.1016/j.pharmthera.2016.03.011
- The paper
- Marcsisin, S. R., Reichard, G., & Pybus, B. S. (2016). Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2016.03.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.